{"prompt": "['Alliance A171601', '11.5.3 Response Criteria', 'All target lesions and target lymph nodes followed by CT/PET-CT/physical examination', 'must be measured on re-evaluation at evaluation times specified in Section 11.2.', 'Specifically, a change in objective status to either a PR or CR cannot be done without re-', 'measuring target lesions and target lymph nodes.', 'Note: Non-target lesions and non-target lymph nodes should be evaluated at each', 'assessment, especially in the case of first response or confirmation of response. In selected', 'circumstances, certain non-target organs may be evaluated less frequently. For example,', 'bone scans may need to be repeated only when complete response is identified in target', 'disease or when progression in bone is suspected.', 'Evaluation of Target Lesions', 'Complete Response (CR): All of the following must be true:', 'Disappearance of all target lesions.', 'Each target lymph node must have reduction in short axis to < 1.0 cm.', 'Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter', 'for all target lesions plus the sum of the short axis of all the target lymph nodes at current', 'evaluation) taking as reference the BSD (see Section 11.5.1).', 'Progression (PD): At least one of the following must be true:', 'At least one new malignant lesion, which also includes any lymph node that was', 'normal at baseline(<1.0cm shortaxis) and increased to > 1.0 cm short axis during', 'follow-up.', 'At least a 20% increase in PBSD (sum of the longest diameter for all target lesions', 'plus the sum of the short axis of all the target lymph nodes at current evaluation)', 'taking as reference the MSD (Section 11.5.1). In addition, the PBSD must also', 'demonstrate an absolute increase of at least 0.5 cm from the MSD.', 'See Section 11.4.2 for details in regards to the requirements for PD via FDG-PET', 'imaging.', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient', 'increase to qualify for PD taking as reference the MSD.', 'Evaluation of Non-Target Lesions & Non-target Lymph Nodes', 'Complete Response (CR): All of the following must be true:', 'Disappearance of all non-target lesions.', 'Each non-target lymph node must have a reduction in short axis to <1.0 cm.', 'Non-CR/Non-PD: Persistence of one or more non-target lesions or non-target lymph', 'nodes', 'Progression (PD): At least one of the following must be true:', 'At least one new malignant lesion, which also includes any lymph node that was', 'normal at baseline (<1.0cmshortaxis) and increased to > 1.0 cm short axis during', 'follow-up.', 'Unequivocal progression of existing non-target lesions and non-target lymph', 'nodes. (NOTE: Unequivocal progression should not normally trump target lesion', '54', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'and target lymph node status. It must be representative of overall disease status', 'change.)', 'See Section 11.4.2 for details in regards to the requirements for PD via FDG-PET', 'imaging.', '11.5.4 Overall Objective Status', \"The overall objective status for an evaluation is determined by combining the patient's status\", 'on target lesions, target lymph nodes, non-target lesions, non-target lymph nodes, and new', 'disease as defined in the following tables:', 'For Patients with Measurable Disease', 'Target Lesions &', 'Non-Target Lesions &', 'New', 'Overall Objective', 'Status', 'Target Lymph Nodes', 'Non-Target Lymph Nodes', 'Sites of Disease', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/Non-PD', 'No', 'PR', 'PR', 'CR', 'No', 'PR', 'Non-CR/Non-PD', 'CR/PR', 'Not All Evaluated*', 'No', 'PR', 'SD', 'CR', 'No', 'SD', 'Non-CR/Non-PD', 'Not All Evaluated*', 'Not all Evaluated', 'CR', 'No', 'Not Evaluated (NE)', 'Non-CR/Non-PD', 'Not All Evaluated*', 'PD', 'Unequivocal PD', 'Yes or No', 'PD', 'CR', 'Non-CR/Non-PD', 'Not All Evaluated*', 'CR/PR/SD/PD/Not all', 'Unequivocal PD', 'Yes or No', 'PD', 'Evaluated', 'CR/PR/SD/PD/Not all', 'CR', 'Yes', 'PD', 'Evaluated', 'Non-CR/Non-PD', 'Not All Evaluated*', '*', 'See Section 11.5.3', '55', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}